Drug Approval | February 03, 2025
Lupin announces closure of USFDA inspection at its Somerset facility with zero 483 observations
The inspection was carried out from January 28 to February 1, 2025
The inspection was carried out from January 28 to February 1, 2025
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population
Mamilli last held the role of Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health at Zoetis
The company remains focused on strengthening its direct retail presence and expanding its reach to more customers across India.
The camp, operational daily from 12 PM to 4 PM, offers free health check-ups, blood pressure monitoring
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinical studies
Earlier, Cupid Limited had been eligible to supply 75% of the contract for female condoms in previous tenders
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
Subscribe To Our Newsletter & Stay Updated
